In distinction, T2DM is an endocrine metabolic disorder, accounting for approximately 90%–95% of all diabetic patients (American Diabetes Association, 2019), due to resistance to insulin action and inadequate compensatory insulin secretory response (American Diabetes Association, 2013). This evidence concerns the gene INS and type 2 diabetes mellitus.